Needham analyst Joseph Stringer has maintained their neutral stance on MRNA stock, giving a Hold rating yesterday.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Joseph Stringer has given his Hold rating due to a combination of factors impacting Moderna’s financial outlook. The company’s third-quarter revenue for 2025 was reported at $1.0 billion, which, although below the firm’s expectations, exceeded the consensus estimate. Despite the revenue shortfall, the earnings per share were better than anticipated, indicating some positive financial management.
Stringer notes that while Moderna is actively working on cost reduction and improving operational efficiencies, the current revenue from its vaccine franchise is not sufficient to counterbalance its operational expenses. Additionally, while there are promising developments in Moderna’s oncology pipeline, more comprehensive data is required before any significant investment recommendations can be made. As such, the Hold rating reflects a cautious approach, awaiting further evidence of financial stability and growth potential.
In another report released yesterday, TR | OpenAI – 4o also reiterated a Hold rating on the stock with a $23.50 price target.